You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Case series of acute arthritis during COVID-19 admission
  1. María-del-Carmen López-González1,
  2. Maria Luisa Peral-Garrido1,
  3. Irene Calabuig2,
  4. Ernesto Tovar-Sugrañes2,
  5. Vega Jovani3,
  6. Pilar Bernabeu2,
  7. Raquel García-Sevila4,
  8. Jose-Manuel León-Ramírez4,
  9. Oscar Moreno-Perez5,6,
  10. Vicente Boix6,7,
  11. Joan Gil4,
  12. Esperanza Merino7,
  13. Paloma Vela6,8,
  14. Mariano Andrés1,6
  1. 1 Seccion de Reumatologia, Hospital General Universitario de Alicante, Alicante, Spain
  2. 2 Reumatología, Hospital General Universitario de Alicante, Alicante, Spain
  3. 3 Rheumatology, Hospital General de Alicante, Alicante, Spain
  4. 4 Neumología, Hospital General Universitario de Alicante, Alicante, Spain
  5. 5 Endocrinologia y Nutricion, Hospital General Universitario de Alicante, Alicante, Spain
  6. 6 Medicina Clínica, Universidad Miguel Hernandez de Elche, Elche, Spain
  7. 7 Unidad de Enfermedades Infecciosas, Hospital General Universitario de Alicante, Alicante, Spain
  8. 8 Rheumatology Department, Hospital General Universitario de Alicante, Alicante, Spain
  1. Correspondence to Dr Mariano Andrés, Seccion de Reumatologia, Hospital General Universitario de Alicante, Alicante 03010, Spain; drmarianoandres{at}gmail.com

https://doi.org/10.1136/annrheumdis-2020-217914

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has changed life significantly worldwide. Rheumatologists also had to get used to the new context, prioritising remote over in-person consultations or solving doubts and giving advice to our immunocompromised patients. Besides, international collaborations have provided opinions concerning decisions that may affect people with rheumatic diseases; for instance, a major provision and use of hydroxychloroquine for COVID-19 might lead to a shortage for patients with lupus or rheumatoid arthritis, as Graef and colleagues point out in their recent viewpoint.1

    In areas of higher impact of the outbreak, as occurred in Spain, some of us have collaborated with colleagues from respiratory medicine and infectious diseases within multidisciplinary teams to face COVID-19. A collateral advantage has been the …

    View Full Text

    Footnotes

    • Contributors All authors took part in data acquisition and analysis. MdCL-G and MA wrote the first draft. All authors approved the final version of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests MA declares speaking fees and research grants from Grunenthal, Menarini and Horizon.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles